VALN · Valneva SE
$5.00
-0.08 (-1.57%)
At close · Jul 17
Market Cap
$510.60M
Shares
102,119,642
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.00
Open$4.99
Day$4.96–5.05
52W$4.96–12.25
Avg vol 30d26K
Short int182K · 0.2% float · 8.4d
Short vol15%
Last earningsSep 30, 2025
DataMay 2021–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−38%
below
Price vs 50-day avg
−9%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−49%
trailing
YTD return
−43%
this year
Relative strength
−57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
2 of 21 funds reported for Jun 30 · net +2.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.18% of float · ▲ +7.9% MoM · 8.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
21 holders — near 3-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Equibles Research
All VALN researchTechnicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−38%
Bearish
Price vs 50-day avg
−9%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
2 of 21 funds reported for Jun 30 · net +2.7K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.18% of float · ▲ +7.9% MoM · 8.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
21 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $5 · 1%
52-wk high $12
vs 200-day avg -38%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VALN
this stock
Valneva SE
|
$510.60M | -43.3% | — | — | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VALN | -1.0% | -6.5% | -48.8% | -4.4% | -43.3% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | +0.6% | -6.9% | -56.7% | -3.9% | -52.3% |